{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:16:06Z","timestamp":1780571766778,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cllc.2025.07.019","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:21:24Z","timestamp":1753806084000},"page":"552-563.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis"],"prefix":"10.1016","volume":"26","author":[{"given":"Mark D.","family":"Danese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shafrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Korytowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.07.019_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cllc.2025.07.019_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2025.07.019_bib0004","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2025.07.019_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0006","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0007","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.3747\/co.23.2936","article-title":"The Brain Metastases Symptom Checklist as a novel tool for symptom measurement in patients with brain metastases undergoing whole-brain radiotherapy","volume":"23","author":"Rodin","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0008","article-title":"Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases","volume":"11","author":"Tan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0009","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.21037\/tlcr.2016.11.01","article-title":"State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer","volume":"5","author":"Inno","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2025.07.019_bib0011","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0012","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1758834017736252","article-title":"Targeted therapy of brain metastases: latest evidence and clinical implications","volume":"9","author":"Di Lorenzo","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0013","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and sagety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0015","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitiors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cllc.2025.07.019_bib0017","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from KRYSTAL-1 trial with KRAS(G12C)-mutated non-small\u2013cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0018","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.07.019_bib0019","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.07.019_bib0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0021","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"suppl 2","key":"10.1016\/j.cllc.2025.07.019_bib0022","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"Trastuzumab deruxtecan in patients with HER2\u2011mutant metastatic non\u2013small cell lung cancer with brain metastases: pooled analyses from DESTINY\u2011Lung01 and DESTINY\u2011Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0023","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.cllc.2025.07.019_bib0024","series-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for non-small cell lung cancer V.6.2025","year":"2025"},{"key":"10.1016\/j.cllc.2025.07.019_bib0025","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0026","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1148\/radiol.212101","article-title":"No prognostic impact of staging brain MRI in patients with stage IA non-small cell lung cancer","volume":"303","author":"Nam","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.cllc.2025.07.019_bib0027","unstructured":"American Cancer Society. Key statistics for lung cancer, 2024. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html#:~:text=Lung%20cancer%20mainly%20occurs%20in,when%20diagnosed%20is%20about%2070. Accessed July 25, 2025."},{"key":"10.1016\/j.cllc.2025.07.019_bib0028","unstructured":"National Cancer Institute. SEER cancer stat facts: lung and bronchus cancer., 2024 \u200bhttps:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html. Accessed July 25, 2025."},{"key":"10.1016\/j.cllc.2025.07.019_bib0029","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.jtho.2022.09.096","article-title":"Treatment patterns, and survival by age in patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) and brain metastases (BM) in the United States","volume":"18","author":"Danese","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0030","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0031","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/1055-9965.EPI-18-1116","article-title":"Lifetime occurrence of brain metastases arising from lung, breast, and skin cancers in the elderly: a SEER-Medicare study","volume":"28","author":"Ascha","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cllc.2025.07.019_bib0032","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.ijrobp.2012.08.007","article-title":"Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States","volume":"85","author":"Halasz","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2025.07.019_bib0033","doi-asserted-by":"crossref","first-page":"e7822","DOI":"10.7717\/peerj.7822","article-title":"Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: a large SEER-based study","volume":"7","author":"Shan","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.cllc.2025.07.019_bib0034","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00432-018-2702-9","article-title":"The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study","volume":"144","author":"Yang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10585-019-10005-2","article-title":"Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study","volume":"37","author":"Ascha","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.cllc.2025.07.019_bib0036","doi-asserted-by":"crossref","first-page":"djw295","DOI":"10.1093\/jnci\/djw295","article-title":"Proportion of never-smoker non\u2013small cell lung cancer patients at three diverse institutions","volume":"109","author":"Pelosof","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2025.07.019_bib0037","first-page":"1","article-title":"Lung cancer in young patients: higher rate of drive mutations and brain involvement, but better survival","volume":"5","author":"Suidan","year":"2019","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0038","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.30539","article-title":"Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma","volume":"123","author":"Tanaka","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.07.019_bib0039","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s12094-018-1838-z","article-title":"Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger","volume":"20","author":"Pan","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oncolo\/oyac094","article-title":"Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases","volume":"27","author":"Huang","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2025.07.019_bib0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2022.05.004","article-title":"Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome","volume":"169","author":"Mogenet","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.07.019_bib0042","unstructured":"American Society of Clinical Oncology. Lung cancer - non-small cell guidelines, 2022 https:\/\/www.cancer.net\/cancer-types\/lung-cancer\/view-all. Accessed July 25, 2025."},{"key":"10.1016\/j.cllc.2025.07.019_bib0043","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0044","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/cancers16030612","article-title":"Social and biological determinants in lung cancer disparity","volume":"16","author":"Brock","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2025.07.019_bib0045","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12913-024-11129-2","article-title":"Barriers to cancer treatment for people experiencing socioeconomic disadvantage in high-income countries: a scoping review","volume":"24","author":"Bourgeois","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.cllc.2025.07.019_bib0046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.archger.2017.05.007","article-title":"Perceived barriers to healthcare and receipt of recommended medical care among elderly Medicare beneficiaries","volume":"72","author":"Kurichi","year":"2017","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.cllc.2025.07.019_bib0047","first-page":"31","article-title":"Understanding and addressing social determinants to advance cancer health equity in the United States: a blueprint for practice, research, and policy","volume":"70","author":"Alcaraz","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2025.07.019_bib0048","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/107755802237808","article-title":"Access to medical care for low-income persons: how do communities make a difference?","volume":"59","author":"Andersen","year":"2002","journal-title":"Med Care Res Rev"},{"key":"10.1016\/j.cllc.2025.07.019_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-060782","article-title":"ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis","volume":"12","author":"Jiang","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.cllc.2025.07.019_bib0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077797","article-title":"Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage","volume":"384","author":"Gupta","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cllc.2025.07.019_bib0052","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.07.019_bib0053","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0054","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.07.019_bib0055","series-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for central nervous system cancer V.1.2025","year":"2025"},{"key":"10.1016\/j.cllc.2025.07.019_bib0056","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:03:46Z","timestamp":1778943826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525730425001639"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.07.019","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}